- Brain signals corresponding to motor intent were reliably captured and converted into digital motor outputs (DMOs) over the 12-month study period NEW YORK--(BUSINESS WIRE)--Synchron, a ...

AI success depends on whether enterprise data is ready, reachable, and close enough to the workloads that need it. In this eSpeaks episode, Dell Technologies’ Vrashank Jain explains why fragmented ...

Synchron's brain-machine interface implant is delivered via catheter, which may reduce the risk of device rejection. () Synchron completed a $10 million Series A round, which will bankroll a ...

Thanks to the success of an initial safety trial for an implantable device that can translate the brain’s electrical impulses into readable signals, we’re a step closer to being able to text—or ...

Synchron, a brain-computer interface (BCI) company, has released the first public demonstration of an individual using an iPad controlled entirely by thought, leveraging Apple’s built-in accessibility ...

Aug 19 (Reuters) - Elon Musk has approached brain chip implant developer Synchron Inc about a potential investment as his own company Neuralink plays catch-up in the race to connect the human brain ...

Sorrento Therapeutics Inc. has divulged antibody-drug conjugates comprising antibodies targeting HER2 covalently linked to exatecan through a linker. They are ...

New York | The private investment vehicles of billionaires Bill Gates and Jeff Bezos have invested in Australia’s New York-based brain-computer interface company, Synchron, a leading competitor to ...

NEW YORK--(BUSINESS WIRE)--Synchron, a brain interface platform company, today announced that the company has secured $40M in a Series B round of financing led by Silicon Valley venture capital firm ...

In an industry-first, the company Synchron and Mount Sinai Hospital in New York have enrolled their first human patient in a U.S. clinical trial called COMMAND to evaluate an endovascular ...

Immuno-oncology company Imugene Ltd. has acquired a worldwide exclusive license to Precision Biosciences Inc.’s allogeneic CD19 CAR T-cell therapy program in a... With a U.S. biotech identified as One ...